Dyne Therapeutics Dividend
Dividend criteria checks 0/6
Dyne Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
n/a
Payout ratio
Industry average yield | 2.9% |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | n/a |
Earnings per share | -US$2.95 |
Dividend yield forecast in 3Y | n/a |
Recent dividend updates
No updates
Recent updates
We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate
May 04Dyne: H2 2024 Muscle Disease Data Could Boost Value
Mar 05We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate
Dec 05Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation
Aug 09We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate
Mar 26We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully
Dec 10Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?
Aug 26Dyne wins regulatory nod to start trial for myotonic dystrophy candidate
Jul 12Dyne stock rises 12% as FDA lifts hold on starting muscle disorder study of DYNE-251
Jul 05Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation
May 05We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely
Jan 12We Think Dyne Therapeutics (NASDAQ:DYN) Can Afford To Drive Business Growth
Sep 29Dyne Therapeutics' chief scientific officer Romesh Subramanian steps down
Jun 02Here's Why We're Not Too Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation
May 12Dyne Therapeutics EPS beats by $0.10
May 06Could The Dyne Therapeutics, Inc. (NASDAQ:DYN) Ownership Structure Tell Us Something Useful?
Jan 27Dyne Therapeutics posts encouraging data from its pre-clinical myotonic dystrophy trial
Jan 11Beneficiary Dyne Therapeutics rises on competitor Sarepta's miss in DMD trial
Jan 08Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if DYN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DYN's dividend payments have been increasing.
Dividend Yield vs Market
Dyne Therapeutics Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (DYN) | n/a |
Market Bottom 25% (US) | 1.5% |
Market Top 25% (US) | 4.7% |
Industry Average (Biotechs) | 2.9% |
Analyst forecast in 3 Years (DYN) | n/a |
Notable Dividend: Unable to evaluate DYN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate DYN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate DYN's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as DYN has not reported any payouts.